^
Association details:
| Biomarker: | TMB-L |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers.
Published date:
05/16/2018
Excerpt:
In those with ≤ median TMB, ToT and OS were higher compared to those with > median TMB (ToT 17 vs. 10 months...efficacy was consistently higher in those with ≤ median TMB...Low TMB is associated with longer time on treatment in patients with metastatic EGFR mutant lung cancers treated with targeted therapy.
DOI:
10.1200/JCO.2018.36.15_suppl.9042
